-- Shilpa Medicare (NSE:SHILPAMED, BOM:530549) has appointed Vellaian Karuppiah as the chief operating officer of formulations, with effect from Thursday, according to a same-day filing to the Indian stock exchanges.
Karuppiah held several high-level positions in various pharmaceutical organizations, including Gland Pharma, Strides Group, Dr. Reddy's Laboratories, Actavis, and Orchid Healthcare, among others.
The company's shares were up nearly 3% in recent trade.
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:ETSY delivered encouraging Q1 2026 results, with revenue of $631M beating the $617M consensus and adj-EBITDA of $185M beating $177M consensus. Etsy marketplace GMS returned to solid 5.5% Y/Y growth, marking a 540 bps improvement from Q4 2025 and the second consecutive quarter of expansion after years of decline. We believe this represents a potential inflection point led by mobile app improvements (personalization and search functions are getting better), with GMS growth accelerating to 11.2% Y/Y. For Q2 2026, ETSY guides for the third consecutive quarter of GMS growth of 3%-5% and full-year low-single digit GMS growth. We're encouraged by improving buyer metrics with active buyers at 86.6M (first sequential growth in two years) and GMS per buyer up 1.8% Y/Y. Take rate expanded 180 bps Y/Y to 25.7% while adj-EBITDA margins improved 100 bps Y/Y to 29.3%. We believe ETSY's strategic transformation is gaining traction but acknowledge an uncertain macro backdrop given the current geopolitical environment.